Ebola Virus Disease Information for Clinicians in U.S. Healthcare Settings
The Centers for Disease Control and Prevention is working closely with the World Health Organization and other partners to better understand and manage the public health risks posed by Ebola virus disease (EVD). As of August 10, 2014, no EVD cases have occurred in the United States. The purpose of this document is to provide updated information about EVD to clinicians working in U.S. hospitals and health clinics.
Patients with EVD generally have abrupt onset of typically 8-10 days after exposure (mean 4-10 days in previous outbreaks, range 2-21 days). Initial signs and symptoms are nonspecific and may include fever, chills, myalgias, and malaise. Fever, anorexia, asthenia/weakness are the most common signs and symptoms. Patients may develop a diffuse erythematous maculopapular rash by day 5 to 7 (usually involving the face, neck, trunk, and arms) that can desquamate.
Due to these nonspecific symptoms particularly early in the course, EVD can often be confused with other more common infectious diseases such as malaria, typhoid fever, meningococcemia, and other bacterial infections (e.g., pneumonia).
Patients can progress from the initial non-specific symptoms after about 5 days to develop gastrointestinal symptoms such as severe watery diarrhea, nausea, vomiting and abdominal pain. Other symptoms such as chest pain, shortness of breath, headache or confusion, may also develop. Patients often have conjunctival injection. Hiccups have been reported. Seizures may occur, and cerebral edema has been reported. Bleeding is not universally present but can manifest later in the course as petechiae, ecchymosis/bruising, or oozing from venipuncture sites and mucosal hemorrhage. Frank hemorrhage is less common. Pregnant women may experience spontaneous miscarriages.
Patients with fatal disease usually develop more severe clinical signs early during infection and die typically between days 6 and 16 of complications including multi-organ failure and septic shock. In non-fatal cases, patients may have fever for several days and improve, typically around day 6-11. Patients that survive can have a prolonged convalescence. The World Health Organization has estimated the mortality of the current outbreak of EVD in West Africa to be approximately 55%, but appears to be as high as 75% in Guinea.
Ebola virus enters the patient through mucous membranes, breaks in the skin, or parenterally and infects many cell types, including monocytes, macrophages, dendritic cells, endothelial cells, fibroblasts, hepatocytes, adrenal cortical cells and epithelial cells. The incubation period may be related to the infection route (i.e., 6 days for injection versus 10 days for contact). Ebola virus migrates from the initial infection site to regional lymph nodes and subsequently to the liver, spleen and adrenal gland. Although not infected by Ebola virus, lymphocytes undergo apoptosis resulting in decreased lymphocyte counts. Hepatocellular necrosis occurs and is associated with dysregulation of clotting factors and subsequent coagulopathy. Adrenocortical necrosis also can be found and is associated with hypotension and impaired steroid synthesis. Ebola virus appears to trigger a release of pro-inflammatory cytokines with subsequent vascular leak and impairment of clotting ultimately resulting in multi-organ failure and shock.
Laboratory findings at admission may include leukopenia frequently with lymphopenia followed later by elevated neutrophils and a left shift. Platelet counts are often decreased in the 50,000 to 100,000 range. Amylase may be elevated, reflecting pancreatic involvement (inflammation/infection). Hepatic transaminases are elevated with aspartate aminotransferase (AST) exceeding alanine aminotransferase (ALT). Proteinuria may be present. Prothrombin (PT) and partial thromboplastin times (PTT) are prolonged and fibrin degradation products are elevated, consistent with disseminated intravascular coagulation (DIC).
Initial evaluation of patients known or suspected to have EVD
Patients known or suspected to have EVD presenting to healthcare settings should be placed in appropriate precautions as soon as possible to prevent transmission of Ebola virus to others. CDC infection control guidance is available here.
Patients from countries currently affected by the Ebola outbreak who present with fever could have other potentially fatal infectious diseases that should be considered in the differential diagnosis, including but not limited to malaria, typhoid fever, and bacterial infections such as pneumonia. Evaluation of febrile illness in a recent traveler should include a thorough travel and exposure history.
Additional information about fever in travelers returning from affected countries is available here.
Health care providers needing assistance with diagnosis or management of suspected cases of malaria should call the CDC Malaria Hotline:
770-488-7788 or 855-856-4713 toll-free (M-F, 9am-5pm, eastern time).
Emergency consultation after hours, call: 770-488-7100 and request to speak with a CDC Malaria Branch clinician.
Non-urgent questions can be emailed to: email@example.com
Travelers from Ebola-affected countries are advised to self monitor their health for 21 days after departure and to seek healthcare if fever and symptoms develop. Travelers with possible exposure to Ebola virus, for example in a healthcare setting, may need additional public health monitoring and movement controls depending on the risk of exposure and clinical presentation. Clinicians should contact the local or state health department to determine whether these measures are needed. CDC Interim Guidance for Monitoring and Movement of Persons with Ebola Virus Disease Exposure.
The current CDC definition for a person under investigation is available at Case Definition for Ebola Virus Disease (EVD).
Illness in a person who has both consistent symptoms and risk factors as follows: 1) Clinical criteria, which includes fever of greater than 38.6 degrees Celsius or 101.5 degrees Fahrenheit, and additional symptoms such as severe headache, muscle pain, vomiting, diarrhea, abdominal pain, or unexplained hemorrhage; AND 2) Epidemiologic risk factors within the past 3 weeks before the onset of symptoms, such as contact with blood or other body fluids of a patient known to have or suspected to have EVD; residence in–or travel to–an area where EVD transmission is active; participation in funeral and burial rituals, or direct handling of bats, rodents, or primates from disease-endemic areas.
Facilities evaluating a person under investigation should contact local or state health department for testing. Health departments should contact CDC EOC (770-488-7100) for testing and consultation.
All laboratory testing should be performed using appropriate laboratory safety guidance. For information regarding guidance of specimen collection, transport, testing and submission for patients with suspected infection with Ebola virus, please see: Interim Guidance: Specimen Collection, Transport, Testing, and Submission. In general, laboratory testing should be kept to the minimum as required for patient care.
There are no approved treatments available for EVD. Clinical management should focus on supportive care of complications, such as hypovolemia, electrolyte abnormalities, refractory shock, hypoxia, hemorrhage, septic shock, multi-organ failure, and DIC.
Recommended care includes volume repletion, maintenance of blood pressure (with vasopressors if needed), maintenance of oxygenation, pain control, nutritional support, as well as treating secondary bacterial infections and pre-existing comorbidities. Some organizations have suggested the addition of broad-spectrum antimicrobials, particularly in patients with evidence of septic shock. Infection prevention and control measures are a critical part of clinical management – all bodily fluids and clinical specimens should be considered potentially infectious.
Several investigational therapeutics for Ebola are in development. For information about availability and access to investigational therapeutics, the manufacturers or the Food and Drug Administration should be contacted.
There are no approved vaccines available for EVD. Several investigational vaccines are in development.